Australia markets close in 3 hours 28 minutes

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.8100+0.0900 (+3.31%)
At close: 04:00PM EDT
2.8900 +0.08 (+2.85%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.7200
Open2.5300
Bid2.4000 x 3200
Ask2.8900 x 1300
Day's range2.4329 - 3.1400
52-week range2.2100 - 18.9600
Volume296,291
Avg. volume424,594
Market cap9.394M
Beta (5Y monthly)0.74
PE ratio (TTM)N/A
EPS (TTM)-0.2490
Earnings date10 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est78.00
  • GlobeNewswire

    Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

    Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety Profile of Only Approved Molecule in US to Treat Symptoms of Acute and Recurrent Diabetic Gastroparesis SOLANA BEACH, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an

  • GlobeNewswire

    Patient Experience Survey Reported Positive Findings for GIMOTI®

    Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTISOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced positive findings from the first patient-centered survey related to GIMOTI. Following the series of market

  • GlobeNewswire

    Evoke Pharma to Present at H.C. Wainwright Global Investment Conference

    SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that its management team will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022. The presentation will be virtual and will provide an overview of the comm